Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: Tire-Kicking Season Continues Full-Swing

Executive Summary

As Roche’s reported interest in buying rare-disease specialist Alexion faded, new suitors popped up for oncology specialist Onyx. Plus news on deals between Spectrum and Talon, Pfizer and Sequella, Medtronic and Amgen, and a new direction for Rexahn.

Advertisement

Related Content

Rexahn Adds Drug Conjugate Platform To Its Oncology Offerings
Spectrum Bets On Marqibo In NHL With Low-Priced Talon Acquisition
Deals Of The Week Wonders: Who Will Buy Onyx?
Onyx Starts Acquisition Process; Price And Competition To Come Into Play
Facing Manufacturing Woes, Alexion Strengthens Leadership
Celgene’s Bet On Abraxis Helps Spur Host Of Nanomedicine Start-Ups
Talon’s Marqibo Faces Commercial Challenges After FDA Approval
Sequella TB Drug Deal Blurs The Line Between Licensing And Financing
Mimetogen Pharmaceuticals Inc.

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS055491

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel